Charles Schwab Investment Management Inc. lifted its stake in Kenvue Inc. (NYSE:KVUE - Free Report) by 2.3% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 24,411,207 shares of the company's stock after purchasing an additional 547,874 shares during the quarter. Charles Schwab Investment Management Inc. owned about 1.27% of Kenvue worth $564,689,000 as of its most recent filing with the Securities & Exchange Commission.
Several other hedge funds and other institutional investors also recently made changes to their positions in KVUE. Riverview Trust Co bought a new stake in shares of Kenvue in the third quarter worth approximately $30,000. Ashton Thomas Securities LLC purchased a new position in shares of Kenvue during the 3rd quarter worth $35,000. Studio Investment Management LLC grew its position in shares of Kenvue by 52.1% during the 2nd quarter. Studio Investment Management LLC now owns 2,468 shares of the company's stock valued at $45,000 after acquiring an additional 845 shares during the period. Deseret Mutual Benefit Administrators raised its holdings in Kenvue by 49.7% in the 3rd quarter. Deseret Mutual Benefit Administrators now owns 1,960 shares of the company's stock worth $45,000 after purchasing an additional 651 shares during the period. Finally, Loring Wolcott & Coolidge Fiduciary Advisors LLP MA bought a new position in shares of Kenvue in the second quarter worth about $61,000. Hedge funds and other institutional investors own 97.64% of the company's stock.
KVUE has been the topic of several recent analyst reports. Piper Sandler lifted their price objective on shares of Kenvue from $20.00 to $21.00 and gave the company a "neutral" rating in a research report on Monday, September 23rd. Jefferies Financial Group assumed coverage on Kenvue in a research note on Tuesday, September 24th. They set a "buy" rating and a $27.00 price target for the company. JPMorgan Chase & Co. raised their target price on shares of Kenvue from $24.00 to $25.00 and gave the company an "overweight" rating in a report on Friday, October 11th. UBS Group increased their price target on shares of Kenvue from $20.00 to $22.00 and gave the company a "neutral" rating in a report on Wednesday, August 7th. Finally, Bank of America increased their price target on Kenvue from $24.00 to $27.00 and gave the company a "buy" rating in a report on Tuesday, October 22nd. One research analyst has rated the stock with a sell rating, seven have issued a hold rating and four have assigned a buy rating to the company. According to MarketBeat, Kenvue currently has an average rating of "Hold" and an average price target of $22.64.
Get Our Latest Stock Analysis on Kenvue
NYSE:KVUE opened at $24.10 on Friday. The company has a market capitalization of $46.21 billion, a PE ratio of 43.82, a P/E/G ratio of 2.15 and a beta of 1.36. Kenvue Inc. has a 52-week low of $17.67 and a 52-week high of $24.24. The stock's 50 day moving average price is $22.81 and its 200 day moving average price is $20.80. The company has a quick ratio of 0.69, a current ratio of 1.00 and a debt-to-equity ratio of 0.66.
Kenvue (NYSE:KVUE - Get Free Report) last announced its quarterly earnings data on Thursday, November 7th. The company reported $0.28 earnings per share for the quarter, beating analysts' consensus estimates of $0.27 by $0.01. Kenvue had a return on equity of 21.43% and a net margin of 6.88%. The company had revenue of $3.90 billion for the quarter, compared to analyst estimates of $3.92 billion. During the same quarter in the previous year, the company earned $0.31 EPS. The firm's revenue for the quarter was down .4% compared to the same quarter last year. On average, research analysts anticipate that Kenvue Inc. will post 1.07 EPS for the current year.
The firm also recently disclosed a quarterly dividend, which will be paid on Wednesday, November 27th. Stockholders of record on Wednesday, November 13th will be given a $0.205 dividend. This represents a $0.82 dividend on an annualized basis and a dividend yield of 3.40%. The ex-dividend date is Wednesday, November 13th. Kenvue's dividend payout ratio is currently 149.09%.
Kenvue Inc operates as a consumer health company worldwide. The company operates through three segments: Self Care, Skin Health and Beauty, and Essential Health. The Self Care segment offers cough, cold and allergy, pain care, digestive health, smoking cessation, eye care, and other products under the Tylenol, Motrin, Benadryl, Nicorette, Zarbee's, ORSLTM, Rhinocort, Calpol, and Zyrtec brands.
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to [email protected].
Before you consider Kenvue, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Kenvue wasn't on the list.
While Kenvue currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.